10-K: Apellis Pharmaceuticals Reports Promising SYFOVRE and EMPAVELI Sales in 2024, Eyes Expansion

Apellis Pharmaceuticals' 2024 10-K filing highlights strong revenue growth from SYFOVRE and EMPAVELI, while outlining strategic initiatives and ongoing clinical developments.

Summary

• Apellis Pharmaceuticals reported a net loss of $197.9 million for 2024, a significant decrease from the $528.6 million loss in 2023 and $652.2 million in 2022.
• The company generated $611.9 million in U.S. net product revenue from SYFOVRE sales and $98.1 million from EMPAVELI sales in 2024.
• Apellis is developing a next-generation therapy combining SYFOVRE with APL-3007, with a Phase 2 trial planned for Q2 2025.
• A supplemental new drug application (sNDA) was submitted to the FDA in early 2025 for EMPAVELI to treat C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
• The Phase 3 VALIANT trial showed a 68% reduction in proteinuria in C3G and IC-MPGN patients treated with EMPAVELI compared to placebo.
• Two new Phase 3 clinical trials with EMPAVELI are planned for H2 2025, targeting primary focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF).
• The company is collaborating with Beam Therapeutics on a gene editing treatment targeting the neonatal Fc receptor (FcRn).
• Apellis withdrew its marketing authorization application (MAA) for SYFOVRE from the European Medicines Agency (EMA) in October 2024.
• The company expects to supply a co-pack for SYFOVRE, containing vials and necessary ancillaries, in the first half of 2026.
• As of December 31, 2024, Apellis had $411.3 million in cash and cash equivalents.
• The company has $375 million of indebtedness under a financing agreement with Sixth Street Lending Partners.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While there's positive revenue growth and promising clinical trial results, there are also ongoing losses, regulatory setbacks, and competitive pressures. The company's strategic initiatives and pipeline development contribute to a moderately positive outlook.

Positives

• Significant revenue growth from SYFOVRE and EMPAVELI.
• Positive results from the Phase 3 VALIANT trial for EMPAVELI in C3G and IC-MPGN.
• Plans to initiate new Phase 3 clinical trials for EMPAVELI in FSGS and DGF.
• Collaboration with Beam Therapeutics for a novel gene editing treatment.
• Decrease in net losses compared to previous years.
• Sobi received EMA validation for its indication extension application for C3G and primary IC-MPGN in the European Union.

Negatives

• Continued net losses despite revenue growth.
• Withdrawal of the marketing authorization application (MAA) for SYFOVRE from the European Medicines Agency (EMA).
• Reliance on third-party manufacturers for drug supply.
• Indebtedness of $375 million under the financing agreement with Sixth Street Lending Partners.
• A small number of patients treated with SYFOVRE in the real world have experienced retinal vasculitis, a severe form of intraocular inflammation.

Risks

• Commercial success of SYFOVRE and EMPAVELI is crucial for future profitability.
• Potential safety issues with SYFOVRE, such as retinal vasculitis, could impact market acceptance.
• Reliance on third-party manufacturers poses supply chain risks.
• Competition from other therapies and companies in the ophthalmology and rare disease markets.
• Regulatory approval processes are lengthy and uncertain.
• Failure to comply with obligations under intellectual property licenses could result in loss of rights.
• Potential product liability claims could divert resources and cause substantial liabilities.
• The trading price of the company's common stock is highly volatile, which could result in substantial losses for stockholders.

Future Outlook

Apellis plans to transform the treatment of GA with SYFOVRE, maximize EMPAVELIs impact in rare diseases, and advance its innovative pipeline, leveraging its complement expertise.

Management Comments

• The company aims to become a leading biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases in areas such as ophthalmology, rare disease, and neurology through the inhibition of the complement system.

Industry Context

The announcement reflects the competitive landscape of the biotechnology and pharmaceutical industries, with a focus on rapidly advancing technologies and a strong emphasis on proprietary products in areas such as ophthalmology, rare diseases, and neurology.

Comparison to Industry Standards

• The document mentions competition in GA from avacincaptad pegol (Izervay) by Astellas Pharma Inc., a C5 inhibitor, and other product candidates in clinical development by Annexon Biosciences, Regeneron Pharmaceuticals, Alnylam Pharmaceuticals, Johnson & Johnson, Aviceda Therapeutics, Boehringer Ingelheim Pharmaceuticals, Stealth BioTherapeutics, Belite Bio, Lineage Cell Therapeutics, Roche/Genentech, ONL Therapeutics, and Ocugen Inc.
• In PNH, the document mentions competition from eculizumab (Soliris) and ravulizumab (Ultomiris) by AstraZeneca, danicopan as an add-on treatment, iptacopan by Novartis AG, and crovalimab by Roche and Chugai Pharmaceutical Co.
• In C3G, the document mentions competition from iptacopan by Novartis, OMS906 by Omeros Corp., KP104 by Kira Pharmaceuticals, and ARO-C3 by Arrowhead Pharmaceuticals.
• In HSCT-TMA, the document mentions competition from ravulizumab by AstraZeneca, nomacopan by Akari, and narsoplimab by Omeros.

Legal Proceedings

• The company and certain of its current and former executive officers are defendants in a purported class action lawsuit initiated in 2023 that alleges, among other things, that the defendants violated Sections 10(b) and/or 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder by misrepresenting and/or omitting certain material facts related to the design of SYFOVREs clinical trials and the risks associated with SYFOVREs commercial adoption.
• The company, its chief executive officer, and its directors are defendants in a purported stockholder derivative lawsuit initiated in 2024 that alleges, among other things that the defendants breached fiduciary duties, were unjustly enriched, committed corporate waste, and violated Section 14(a) of the Exchange Act based on the same facts.
• In August 2024, an individual filed a civil action against the Company in the United States District Court in the Northern District of Texas, alleging personal injury claims in connection with the use of SYFOVRE.

Stakeholder Impact

• Shareholders: Potential for long-term growth and value creation, but also risk of stock price volatility and dilution.
• Employees: Opportunity for career growth and development, but also risk of job insecurity due to company performance or restructuring.
• Patients: Access to innovative therapies for serious diseases, but also risk of side effects and high costs.
• Customers: Access to new products and services, but also potential for price increases and changes in coverage.
• Suppliers: Opportunity for increased business, but also risk of contract termination or renegotiation.
• Creditors: Potential for repayment of debt, but also risk of default or restructuring.

Next Steps

• Initiate a Phase 2 multi-dose trial in patients with GA in the second quarter of 2025.
• Initiate two new Phase 3 clinical trials with EMPAVELI in the second half of 2025 for the treatment of primary focal segmental glomerulosclerosis, or FSGS, and delayed graft function, or DGF.
• Sobi expects to report top-line on this study in mid-2025.
• Supply of the co-pack to be available in the first half of 2026.

Key Dates